logo
Why the tariff relief stock rally isn't shaking Wall Street's biggest bear

Why the tariff relief stock rally isn't shaking Wall Street's biggest bear

Yahoo28-04-2025

Stocks may be in tariff relief rally mode, but Wall Street's biggest bear says investors should stay on high alert given the volatile backdrop.
"President Trump's decision to walk back part of his tariff hikes has reduced the odds of a deep US recession. Nevertheless, stocks are not priced for even a mild recession, which suggests that the risk to equities is to the downside," BCA Research chief strategist Peter Berezin warned in a new note.
Berezin gained attention for being the lone bear on Wall Street coming into 2025. Further, he correctly called in 2022 that there would be no US recession, despite most on the Street bracing for one. He has been an economist for more than 30 years, with stints at the International Monetary Fund (IMF), Goldman Sachs, and now BCA Research.
There are several reasons Berezin is staying the course with his calls for a 75% chance of a US recession this year and S&P 500 (^GSPC) to finish at 4,450 (current level: 5,525).
First, the current effective US tariff rate is still the highest since at least the 1930s, Berezin pointed out. The uncertainty around tariffs is beginning to cause companies to rein in capital expenditures, which could have ramifications for the job market.
Read more: What Trump's tariffs mean for the economy and your wallet
The uncertainty and potential tariff-related price hikes could also weigh on the spending decisions of US consumers.
"We have these wired homes with the permission of consumers, we can track exactly what's happening in the laundry room, for example, how many loads are done per week, what temperature are those loads, etc.," Procter & Gamble (PG) CEO Jon Moeller told Yahoo Finance last week. "And what you see is a reduction in the number of loads that are done per week, currently going from about, if you go all the way back pre-COVID, about five loads per week to now about three and a half."
The consumer staples giant cut its full-year sales and profit outlooks owing to economic concerns.
Second, recent economic data studied by Berezin suggests that the US economy was softening before the trade war began.
The Atlanta Fed GDP tracker pegs first quarter GDP as having dropped 0.4%. Goldman Sachs economists said GDP contracted 0.2% in the first quarter.
Consumer sentiment indicators also began to weaken in March versus prior months.
On stocks specifically, Berzin's analysis showed markets aren't pricing in a "meaningful deterioration in economic growth," let alone a "full blown" recession.
The forward price-to-earnings (PE) multiple on the S&P 500 stands at 19.9 times, which is well below the level seen in past recessions. For example, during the March 2020 COVID-19 crisis, the S&P 500's PE multiple hit a low of 13.4 times. During the Great Financial Crisis, the S&P 500's PE multiple hit a low of 8.9 times in November 2008.
"US stocks will under-perform on a multi-year horizon," Berezin wrote.
The call from the closely followed strategist comes as stocks have rallied back on signs of the Trump administration being more open to tariff negotiations.
Japan's Topix Index closed Monday at 2,650.61, just above the close on April 2 before Trump unveiled his tariff scheme.
The S&P 500 has seen a four-day rally in spite of a spate of mixed earnings reports from the likes of household name companies, such as PepsiCo (PEP).
The index is up 12% from its April 8 trough (but still down 10% from its peak).
"We think there are two different (legitimate) perspectives at play on the consumer, which may be adding to investor confusion," RBC strategist Lori Calvasina wrote in a note on Monday. "We exited the week seeing managing tariff impacts as a work in progress, but with a greater appreciation of the work that has been done."
Brian Sozzi is Yahoo Finance's Executive Editor. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email brian.sozzi@yahoofinance.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030
Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030

Yahoo

time33 minutes ago

  • Yahoo

Monoclonal Antibody Segment Set for Significant Expansion, Reaching $2 Billion by 2030

Antibody discovery, crucial for developing targeted therapies in fields like oncology and autoimmune diseases, is evolving with innovations like phage display and AI-driven design. The market is booming across North America, Europe, and Asia-Pacific, driven by personalized medicine and rapid advancements in antibody discovery technologies. Antibody Discovery Market Dublin, June 02, 2025 (GLOBE NEWSWIRE) -- The "Antibody Discovery - Global Strategic Business Report" has been added to global market for Antibody Discovery was valued at US$1.9 Billion in 2024 and is projected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Antibody Discovery market. Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase - encompassing target identification, antibody generation, screening, and lead optimization - is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques - ranging from chimerization to full deimmunization - are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific - especially China, South Korea, and Japan - is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases - including rheumatoid arthritis, psoriasis, and Crohn's disease - also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer's, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across Is Fueling the Growth of the Global Antibody Discovery Market?The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market - such as trastuzumab, adalimumab, and pembrolizumab - which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges - can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?Report ScopeThe report analyzes the Antibody Discovery market, presented in terms of market value (US$ Thousand). The analysis covers the key segments outlined Antibody Type (Monoclonal, Polyclonal, Other Antibody Types) Service (Phage Display, Hybridoma, Other Services) End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses) Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibody segment, which is expected to reach US$2 Billion by 2030 with a CAGR of a 9.3%. The Polyclonal Antibody segment is also set to grow at 10.9% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $500.0 Million in 2024, and China, forecasted to grow at an impressive 9.5% CAGR to reach $530.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam, AbCellera Biologics, Ablexis, Adimab, Akeso Biopharma and more. Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities. Key Attributes: Report Attribute Details No. of Pages 224 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.9 Billion Forecasted Market Value (USD) by 2030 $3.3 Billion Compound Annual Growth Rate 9.8% Regions Covered Global Key Topics Covered: MARKET OVERVIEW World Market Trajectories Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines Transgenic Animal Models Expand the Scope of Novel Antibody Generation Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery Data Integration Across Platforms Enhances Efficiency in Antibody Optimization Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery FOCUS ON SELECT PLAYERSSome of the 41 companies featured in this Antibody Discovery market report include: Abcam AbCellera Biologics Inc. Ablexis Adimab Akeso Biopharma Biocytogen Pharmaceuticals Co., Ltd. Bruker Corporation Charles River Laboratories ChemPartner Creative Biolabs Danaher Corporation Eurofins Scientific Evotec SE FairJourney Biologics Genmab GenScript Biotech Corporation Harbour BioMed Icosagen AS ImmunoPrecise Antibodies Ltd. Isogenica Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Discovery Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store